Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Platelet aggregation ratio" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A kind of assay method and equipment for platelet aggregation and coagulation factor
ActiveCN102262090AFast testProtect your healthMaterial analysis by optical meansPlatelet aggregation ratioTurbidimetry
The invention relates to a method for measuring the platelet aggregation and a blood coagulation factor. In the method, a full-automatic coagulate blood analytical instrument is used, the platelet aggregation is measured by using photoelectric turbidimetry and the blood coagulation factor is measured by using a double magnetic circuit and bead method. The method comprises the following measuring steps of: preparing a platelet aggregation inductive agent, platelet rich plasma and platelet poor plasma; respectively reading light transmittance data of a platelet poor plasma sample and light transmittance data of a platelet rich plasma sample as well as light transmittance data of the platelet rich plasma during the forming process of the platelet aggregation within the specified time; calculating the platelet aggregation rate of the measured blood sample; absorbing the platelet poor plasma and injecting the platelet poor plasma in a hemagglutination cup; absorbing the selected reagent according to a test program and injecting the selected reagent into the hemagglutination cup; automatically monitoring the amplitude of a steel bead; and generating a test report by using measuring results of the platelet aggregation and the blood coagulation factor according to input information of patients.
Owner:BEIJING PRECIL INSTR CO LTD +1
Sulfonated changium root polysaccharides and preparing method and use thereof
InactiveCN1844160ANovel preparation processLow costOrganic active ingredientsAntineoplastic agentsChangiumSulfated polysaccharides
In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides' molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Medicament for treating chronic cerebral circulation insufficiency and preparation method
ActiveCN101940765BConvenient treatmentReduce high shear viscosityCardiovascular disorderPlant ingredientsSalvia miltiorrhizaGastrodia
Owner:QIANFOSHAN HOSPITAL OF SHANDONG
Optimized automation-adaptable platelet aggregation function inspection and analysis method
The invention provides an optimized automation-adaptable platelet aggregation function inspection and analysis method, and belongs to the field of clinical laboratory medicine. The method is an improvement and optimization of a platelet aggregation function inspection and analysis method using an automation counting method. The method is suitable for platelet aggregation function automatic analysis instruments using the counting method. According to the method, the number of platelets is inspected and recorded and an aggregation rate is calculated. A laboratory test result shows that the method is better in repeatability of the obtained result of platelet aggregation rate compared with a previous largest aggregation rate method.
Owner:SINNOWA MEDICAL SCI & TECH
Platelet aggregation determination method based on high throughput detection and application thereof to drug screening
The invention discloses a platelet aggregation determination method based on high throughput detection. The method comprises the following steps: extracting a platelet sample with activity from an organism, and diluting a platelet suspension through a solvent; and transferring into a microplate for incubation, adding a stimulant of certain concentration, and determining with a dynamical method of a microplate reader, thereby obtaining the platelet aggregation rate. The method can be applied to rapid clinical evaluation on activity of platelets and high throughput screening of antithrombotic drugs at multiple targets, and is implemented through a cyclooxygenase inhibitor, an ADP receptor inhibitor, a protein activating enzyme receptor inhibitor, a platelet surface GPIIb / IIIa receptor inhibitor and the like.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Application of atractylenolide-II derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug
ActiveCN104490868ASimple compositionGood curative effectOrganic active ingredientsAntipyreticTreatment effectSide effect
The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-II derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-II derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Application of atractylenolide-III derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug
ActiveCN104490869ASimple compositionGood curative effectOrganic active ingredientsBlood disorderAtractylenolide IIISide effect
The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-III derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-III derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Method for determination of platelet aggregation rate
InactiveCN105938096AReduced risk of exposure to samplesReduce operating errorsTransmissivity measurementsPlatelet aggregation ratioTurbidimetry
The invention relates to a method for determination of platelet aggregation rate. The method conducts determination on the basis of photoelectric turbidimetry, and comprises the determination steps of: placing prepared platelet-rich plasma onto a sample plate device, imbibing the platelet-rich plasma, injecting into a test cup of a test movement device, and reading the transmittance data of the platelet-rich plasma sample; imbibing a platelet aggregation inducer, injecting into a test cup, reading the transmittance data of the platelet-rich plasma sample within a specified time in the formation process of platelet aggregation; imbibing a strong inducer or a composite inducer, injecting into a test cup, conducting continuous detection on the test cup by a platelet aggregation test device; when all platelets in the platelet-rich plasma nearly reach the aggregation state and the maximum transmittance is reached, automatically reading the transmittance data; and calculating the maximum aggregation rate of the platelet of the measured blood sample, and generating a test report according to the input patient information.
Owner:山东泰利信医疗科技有限公司
Oral caring composition and application thereof in inhibiting gum bleeding
InactiveCN110870870AResolve the bleedingAvoid bleedingCosmetic preparationsOrganic active ingredientsBleeding gumPlatelet aggregation ratio
The invention discloses an oral caring composition which comprises asiatic centella triterpenoids and an orally acceptable carrier, wherein the triterpenoids comprise one of or a combination of more of asiaticoside, asiaticoside degradation products, hydroxy asiaticoside and hydroxyl asiaticoside degradation products. The invention further discloses application of the asiatic centella triterpenoids in inhibiting gum bleeding. Four blood coagulation indexes of the oral caring composition disclosed by the invention meet standards that the prothrombin time (PT) is less than or equal to 14.5 seconds, the thrombin time (TT) is less than or equal to 42.5 seconds, the activated part thromboplastin time (APTT) is less than or equal to 27.0 seconds, and the platelet aggregation rate is greater thanor equal to 53.5. The problem of gum bleeding can be effectively solved.
Owner:HAWLEY & HAZEL BVI
Yak skin polypeptide with effect of affecting platelet aggregation and preparation method thereof
InactiveCN109879932AIncrease economic value addedWide variety of sourcesHydrolysed protein ingredientsPeptide preparation methodsNutritionPlatelet aggregation ratio
The invention relates to the field of medicines, in particular to yak skin polypeptide with an effect of affecting platelet aggregation and a preparation method thereof. The yak protein is composed of17KDa, 34 KDa and 43 KDa in molecular weight. The maximum ultraviolet absorption wavelength of a peptide bond is at the 216nm position, the infrared spectrum of an amide I band is at the 1600-1700 cm-1 position, the infrared spectrum of an amide II band is at the 1560-1500cm position, and the infrared spectrum of the amide III is at the 1234-1237 cm-1 position. The preparation method includes buffing, heating, foaming, enzymatic hydrolysate preparation, centrifugal concentration and separation and drying. The pure natural pollution-free Qinghai-Tibet Plateau yak skin is used as the main raw material, the raw material source is wide, and the nutrition is rich. A product with the effect of affecting platelet aggregation is increased while the economic value added of the yak skin is increased. The polypeptide is simple in preparation and operation process. The prepared yak skin polypeptide has three molecular weight segments of bioactive components affecting the platelet aggregation, andthe platelet aggregation rate in vitro of mice is 38.4%.
Owner:CHINA ACAD OF SCI NORTHWEST HIGHLAND BIOLOGY INST
New multifunctional platelet detecting instrument
The invention discloses a new multifunctional platelet detecting instrument which is a multifunctional detecting instrument with the functions of detecting the number, the volume size and the aggregation rate of platelets. The instrument realizes the function of detecting the aggregation ability (aggregation rate) of the platelets by detecting the changes of the platelets after platelet agonist is added. The blood sample which is not subjected to separation process is directly adopted to detect by the instrument; the operation process is convenient, influencing factor is few, and during the detecting process, the sample processing conditions (temperature, time, dosage of the reagent and so on) is automatically controlled to be consistent by the instrument, so the detection result is more reliable.
Owner:SINNOWA MEDICAL SCI & TECH
Method for judging measuring result of platelet aggregation rate and calibration method of platelet aggregator
ActiveCN109406461ASave resourcesThe testing process is simpleTransmissivity measurementsPlatelet aggregation ratioMedicine
The invention provides a method for judging the measuring result of the platelet aggregation rate. The method comprises the following steps: a normal whole blood sample is selected, the anaemic platelet plasma transmittance PPP0 and the blood-rich platelet plasma transmittance PRP0 are measured, and the transmittance difference P0 of the whole blood sample is calculated, wherein P0=PPP0-PRP0; a measured whole blood sample is selected, the anaemic platelet plasma transmittance PPP and the blood-rich platelet plasma transmittance PRP are measured, and the transmittance difference P of the measured sample is calculated, wherein P=PPP-PRP; the platelet separation degree index DI of the measured sample is calculated, wherein DI=P / P0=(PPP-PRP) / (PPP0-PRP0); the platelet aggregation rate of blood-rich platelet plasma is measured through a platelet aggregator; and whether the measured platelet aggregation rate is reliable or not is judged according to the platelet separation degree index DI ofthe measured sample. According to the method for judging the measuring result of the platelet aggregation rate, by referring to the platelet separation degree index of the measured sample, the measuring result of the platelet aggregation rate of the measured sample is judged reliably.
Owner:山东泰利信医疗科技有限公司
Use of atractylenolide compound or its derivatives and a medicament for inhibiting platelet aggregation
ActiveUS20160324825A1Improve efficacyTendency of toleranceOrganic active ingredientsPharmaceutical delivery mechanismDiseaseSide effect
A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Optimized platelet aggregation function detection analysis method suitable for automated instrument
An optimized platelet aggregation function detection analysis method suitable for automated instrument belongs to the field of clinical laboratory medicine. The method is an improvement and optimization of an automatic counting detection method for detection analysis of platelet aggregation function. The process is applicable to platelet aggregation function automated analytical instrument employing a counting method. The method detects and records the amount of platelet and calculates aggregation rate. Test results by the laboratory show that the repeatability of the platelet aggregation rate result obtained by the method is superior to that of a prior maximum aggregation rate method.
Owner:SINNOWA MEDICAL SCI & TECH
Application of butyric acid compound in preparing drug or functional food for treating ischemic stroke
InactiveCN110151744AImprove securityRestoring damaged nerve functionNervous disorderMetabolism disorderDyslipidemiaPlatelet aggregation ratio
The invention discloses application of a butyric acid compound in preparing a drug or functional food for treating ischemic stroke. The drug or the functional food comprises the butyric acid compound,wherein the concentration of the butyric acid compound is 20-100 micromoles per liter, and the effective dose of the butyric acid compound as the drug is 5-50 mg / kg / d. After oral administration, thebutyric acid compound can effectively reduce the area of cerebral infarction, significantly restore the neurological damages caused by the ischemic stroke, ameliorate dyslipidemia caused by the ischemic stroke, and effectively reduce the blood viscosity, the fibrinogen content and the platelets aggregation rate, thereby ameliorating the complications induced by the ischemic stroke in many aspectsand effectively treating the ischemic stroke.
Owner:SOUTHERN MEDICAL UNIVERSITY
Medicament for treating chronic cerebral circulation insufficiency and preparation method
ActiveCN101940765AConvenient treatmentReduce high shear viscosityCardiovascular disorderPlant ingredientsSalvia miltiorrhizaGastrodia
The invention discloses a medicament for treating the chronic cerebral circulation insufficiency and a preparation method. The medicament comprises salvia, codonopsis, coptis, chuanxiong, zedoary, crataegus, seaweed, gastrodia, coix seed and curcuma as raw materials. The preparation method comprises the following steps of: adding water to the coptis for decoction, concentrating the water decoction into thick paste, adding water to other raw materials for decoction, concentrating the water decoction into thick paste, combing the two pieces of thick paste, adding a suitable amount of dextrin, and uniformly mixing, drying, crushing and pelletizing the mixture. The medicament has the effects of simultaneously removing blood stasis, promoting blood circulation, eliminating phlegm and invigorating spleen, can better treat the arteriosclerosis, remarkably improve the integral of syndrome of intermingled phlegm and blood stasis for the granule fraction of removing blood stasis and promoting blood circulation, has better effects of reducing the whole blood high-shear viscosity, low-shear viscosity, plasma viscosity and platelet aggregation ratio, and has the advantages of high safety and no influence on hemogram, liver and kidney functions and the like.
Owner:QIANFOSHAN HOSPITAL OF SHANDONG
Application of isolated compounds from Salvia deserta Schang in preparation of drug with anti-platelet aggregation effect
InactiveCN104473913AReduce aggregation rateHigh inhibition rateEster active ingredientsBlood disorderBiotechnologySalvia miltiorrhiza
The invention discloses an application of isolated compounds from Salvia deserta Schang in the preparation of a drug with the anti-platelet aggregation effect. The application of the isolated compounds from Salvia deserta Schang in the preparation of the drug with the anti-platelet aggregation effect provided by the invention has the following benefits: according to in-vitro anti-platelet aggregation experiments on 7-O-acetylhorminone and horminone, the two componential monomers achieve better anti-platelet aggregation effect, certain quality dependency is shown among various concentration groups, and certain time dependency is shown among high concentration groups of the two components based on the fact that as time passes by, the platelet aggregation rate decreases and the inhibition rate increases; anti-platelet aggregation activity results indicate better activity of the two components, so that certain development and utilization value are achieved. The application can make up for the regional defect that Salvia miltiorrhiza drugs are absent in Xinjiang, thereby having remarkable market prospects.
Owner:XINJIANG MEDICAL UNIV
Essential oil for activating blood and dredging collaterals and preparation method thereof
InactiveCN107334822ASignificantly reduce platelet aggregation rateHigh extraction rateEssential-oils/perfumesBlood disorderPlatelet aggregation ratioThrombus
The invention belongs to the technical field of Chinese medicine, and particularly relates to essential oil for activating blood and dredging collaterals. The essential oil comprises, by weight, 40-90 parts of jizhou mugwort leaf essential oilx, 30-70 parts of rhizoma corydalis essential oil, 36-76 parts of perilla leaf essential oil, 20-87 parts of garden balsam stem essential oil, 40-68 parts of carthamus tinctorius essential oil, 42-77 parts of chuanxiong rhizome essential oil and 30-75 parts of suberect spatholobus stem essential oil. The Chinese herbs are used as raw materials, an oxidation-resistant extracting solution is adopted for extracting the essential oil, and then all the essential oil is mixed according to a proportion to obtain the essential oil. The essential oil for activating blood and dredging collaterals has the remarkable effects that the aggregation rate of platelets is remarkably decreased, and blood viscosity and the wet weight of thrombus are remarkably reduced, and the effect of activating blood and dredging collaterals is remarkable; in the essential oil for activating blood and dredging collaterals, the chuanxiong rhizome essential oil and suberect spatholobus stem essential oil have a synergistic effect. The oxidation-resistant extracting solution is adopted for extracting the essential oil, so that the extracting rate of essential oil components is increased.
Owner:赵铄杰
Artemisia argyi preparatum traditional Chinese medicine compound with stronger hemostasis function, preparation method and application
ActiveCN107213206AGood hemostasisThe hemostatic effect is quiteBlood disorderExtracellular fluid disorderPlatelet adhesivenessPlatelet aggregation ratio
The invention belongs to the field of the traditional Chinese medicine and specifically relates to a traditional Chinese medicine compound with a stronger hemostasis function. An artemisia argyi preparatum traditional Chinese medicine compound with the stronger hemostasis function is prepared from the following raw materials: artemisia argyi preparatum, radix angelicae and vinegar processed corydalis tuber. The artemisia argyi preparatum traditional Chinese medicine compound can be used as a hemostasis drug or a main component in the hemostasis drug. According to the invention, the artemisia argyi preparatum is taken as the main component and the radix angelicae and the vinegar processed corydalis tuber are taken as auxiliary components; the determination for plasma recalcification time, the determination for platelet aggregation rate, the determination for thrombin activity promoting rate and the determination for platelet adhesiveness rate prove that the hemostasis effect of the artemisia argyi preparatum traditional Chinese medicine compound is obviously better than that of single artemisia argyi preparatum and is equivalent to that of Yunnan Baiyao powder; and the artemisia argyi preparatum traditional Chinese medicine compound can be used as a daily or clinical hemostasis drug.
Owner:HUIZHOU UNIV
Method and equipment for measuring platelet aggregation and blood coagulation factor
ActiveCN102262090BFast testProtect your healthMaterial analysis by optical meansPlatelet aggregation ratioTurbidimetry
The invention relates to a method for measuring the platelet aggregation and a blood coagulation factor. In the method, a full-automatic coagulate blood analytical instrument is used, the platelet aggregation is measured by using photoelectric turbidimetry and the blood coagulation factor is measured by using a double magnetic circuit and bead method. The method comprises the following measuring steps of: preparing a platelet aggregation inductive agent, platelet rich plasma and platelet poor plasma; respectively reading light transmittance data of a platelet poor plasma sample and light transmittance data of a platelet rich plasma sample as well as light transmittance data of the platelet rich plasma during the forming process of the platelet aggregation within the specified time; calculating the platelet aggregation rate of the measured blood sample; absorbing the platelet poor plasma and injecting the platelet poor plasma in a hemagglutination cup; absorbing the selected reagent according to a test program and injecting the selected reagent into the hemagglutination cup; automatically monitoring the amplitude of a steel bead; and generating a test report by using measuring results of the platelet aggregation and the blood coagulation factor according to input information of patients.
Owner:BEIJING PRECIL INSTR CO LTD +1
Method for judging platelet aggregation rate measurement results and calibration method for platelet aggregation meter
ActiveCN109406461BReliable judgmentEasy to operateTransmissivity measurementsPlatelet aggregation ratioWhole blood units
The invention provides a method for judging the measurement result of platelet aggregation rate, comprising the following steps: selecting a normal whole blood sample, measuring the transmittance PPP0 of platelet-poor plasma and the transmittance PRP0 of platelet-rich plasma, and calculating the ratio of the transmittance of the whole blood sample Difference P0=PPP0-PRP0; select the whole blood sample to be tested, measure the platelet-poor plasma transmittance PPP and platelet-rich plasma transmittance PRP, and calculate the difference between the transmittance of the tested sample P=PPP-PRP; calculate the measured The platelet separation index DI=P / P0=(PPP-PRP) / (PPP0-PRP0) of the sample; the platelet aggregation rate of platelet-rich plasma is measured by a platelet aggregometer; according to the platelet separation index DI of the tested sample, the determination measurement Whether the platelet aggregation rate is reliable. The invention reliably judges the measurement result of the platelet aggregation rate of the tested sample by referring to the platelet separation index of the tested sample.
Owner:山东泰利信医疗科技有限公司
Use of atractylenolide compound or its derivatives and a medicament for inhibiting platelet aggregation
ActiveUS9642832B2Improve efficacyTendency of toleranceOrganic active ingredientsPharmaceutical delivery mechanismDiseaseSide effect
A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Medicinal mixture for treating arrhythmia
InactiveCN1895245AAvoid hydrolysisReduce conduction velocityCardiovascular disorderHeterocyclic compound active ingredientsValsartanPlatelet aggregation ratio
Owner:李为民 +2
Platelet aggregation rate detection method and detection device
PendingCN112526144AAvoid the effects of aggregationImprove accuracyBiological testingPlatelet aggregation ratioMagnetic bead
The invention discloses a platelet aggregation rate detection method which comprises the steps: activating and aggregating platelets, crosslinking the platelets with magnetic beads coated with fibrinogen on the surfaces, aggregating the crosslinked activated platelets to a certain specific area by using magnetic force, and measuring the concentration of unactivated platelets in samples in other areas; and calculating the platelet aggregation rate according to the initial concentration of the platelets and the concentration of the unactivated platelets. By adopting the method provided by the invention, the influence on platelet aggregation in the detection process and the influence on quantity measurement caused by different aggregation conditions of platelets are avoided, and the detectionaccuracy is effectively improved.
Owner:滁州瑞谷生物技术有限公司
Application of Atractylolide Ⅲ Derivatives in Preparation of Anti-platelet Aggregation Drugs and Anti-Platelet Aggregation Drugs
ActiveCN104490869BSimple compositionGood curative effectOrganic active ingredientsBlood disorderAtractylenolide IIISide effect
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
In-vitro evaluation model and method for hemostatic performance of toothpaste containing bletilla striata extract
PendingCN110849835AReduce and avoidMeet R&D needsPreparing sample for investigationColor/spectral properties measurementsBiotechnologyPlatelet aggregation ratio
The invention discloses an in-vitro evaluation model and an in-vitro evaluation method for hemostatic performance of toothpaste containing a bletilla striata extract. Evaluation indexes of the in-vitro evaluation model comprise at least one of platelet aggregation rate, cyclic adenosine monophosphate (cAMP) and thromboxane B2 (TXB2) content. The in-vitro evaluation method comprises the steps of: acquiring arterial blood of an animal, centrifuging the arterial blood, adjusting plasma concentration, and detecting absorbance OD0 when the arterial blood is blank; respectively adding a toothpaste sample containing bletilla striata extracts with different concentrations and a control sample into a pore plate filled with blood plasma, slightly oscillating the samples, incubating the samples at aconstant temperature of 37 DEG C for full reaction, and adding an adenosine diphosphate solution into the samples to induce platelet aggregation reaction; and testing plasma absorbance ODt and contentof cAMP and TXB2 when the turbidity in the reaction system changes, and calculating a platelet aggregation rate for evaluating the hemostatic performance of the toothpaste. The in-vitro evaluation model and the in-vitro evaluation method effectively reduce and avoid the usage of experimental animals, can greatly improve the working efficiency of toothpaste formula research, and reduce the in-vivotest cost.
Owner:SHANGHAI OCEAN UNIV
Gastrodin derivatives, their preparation methods, their applications and pharmaceutical preparations
ActiveCN106243168BSignificant anticoagulant effectOrganic active ingredientsSugar derivativesDiseasePlatelet aggregation ratio
The invention provides a gastrodin derivative and a preparation method thereof. The gastrodin derivative contains substituted indene ring. The invention also provides a preparation method of the gastrodin derivative. A turbidimetry is used for determining a platelet aggregation rate so as to evaluate an inhibition rate of the gastrodin derivative for the platelet aggregation. An experiment result shows that the gastrodin derivative has an obvious anticoagulation effect and can be used as a potential lead compound in preparing drugs for treating thrombus, cardiovascular and cerebrovascular diseases, stroke and other diseases associated with blood coagulation.
Owner:KPC PHARM INC
Gastrodin derivative, preparation method and applications thereof, and medicinal preparation
ActiveCN106336442ASignificant anticoagulant effectOrganic active ingredientsSugar derivativesDiseasePlatelet aggregation ratio
The invention provides a gastrodin derivative and a preparation method thereof. The gastrodin derivative contains a substituted naphthalene ring. The invention also provides the preparation method of the gastrodin derivative, The platelet aggregation rate is determined through adopting a turbidimetric technology, and is used to evaluate the inhibition rate of the gastrodin derivative on platelet aggregation. An experiment result shows that the gastrodin derivative has an obvious anticoagulation effect, and can be applied to the preparation of medicines for treating thrombus, cardiovascular and cerebrovascular diseases, stroke and other blood aggregation related diseases as a potential lead compound.
Owner:KPC PHARM INC
Gastrodin derivative, and preparation method, application and medicinal preparation of gastrodin derivative
ActiveCN106243168ASignificant anticoagulant effectOrganic active ingredientsSugar derivativesDiseasePlatelet aggregation ratio
The invention provides a gastrodin derivative and a preparation method thereof. The gastrodin derivative contains substituted indene ring. The invention also provides a preparation method of the gastrodin derivative. A turbidimetry is used for determining a platelet aggregation rate so as to evaluate an inhibition rate of the gastrodin derivative for the platelet aggregation. An experiment result shows that the gastrodin derivative has an obvious anticoagulation effect and can be used as a potential lead compound in preparing drugs for treating thrombus, cardiovascular and cerebrovascular diseases, stroke and other diseases associated with blood coagulation.
Owner:KPC PHARM INC
Sulfonated changium root polysaccharides and preparing method and use thereof
InactiveCN100369936CNovel preparation processLow costOrganic active ingredientsAntineoplastic agentsChangiumSulfated polysaccharides
In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides' molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com